{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:54:37Z","timestamp":1790848477358,"version":"4.1.0"},"reference-count":33,"publisher":"Tech Science Press","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["oncol res"],"published-print":{"date-parts":[[2017,11,2]]},"abstract":"<jats:p>Adherence has become an important issue in modern oncology treatment. Most studies have included heterogeneous target tumor types, regimens, and therapy settings. Our study focused on capecitabine during capecitabine plus oxaliplatin (XELOX) treatment as an adjuvant therapy for colorectal cancer. The main aims of this study were to evaluate real-life adherence to capecitabine and to investigate candidate factors that might decrease adherence. We studied 338 consecutive patients who received XELOX treatment between December 1, 2011, and April 30, 2015, at the Cancer Institute Hospital of the Japanese Foundation for Cancer Research. Our study assessed adherence to capecitabine through patient-reported treatment diaries and interviewed nonadherents to determine the reasons for not taking capecitabine at a pharmaceutical outpatient clinic. We calculated the adherence rate in a cycle as: number of times the patient took capecitabine\/28. Relative dose intensities and factors associated with deteriorating adherence to capecitabine were retrospectively surveyed from electronic patient records. Uni- and multivariate logistic regression analyses were used to investigate factors associated with optimal adherence. The study covered 282 patients who received 2,055 cycles of XELOX. Median adherence rate was 94.0% in the first cycle, and median relative dose intensity of capecitabine was 77.8%. The most common reasons for nonadherence were nausea\/vomiting and diarrhea. The presence of the following factors was not significantly associated with adherence: ECOG performance status \u22651 (<jats:italic>p<\/jats:italic>\u2009=\u20090.715), clinical stage (<jats:italic>p<\/jats:italic>\u2009=\u20090.408), primary tumor site (<jats:italic>p<\/jats:italic>\u2009=\u20090.576), age \u226570 years at study entry (<jats:italic>p<\/jats:italic>\u2009=\u20090.757), female gender (<jats:italic>p<\/jats:italic>\u2009=\u20090.504), and not living alone (<jats:italic>p<\/jats:italic>\u2009=\u20090.579). The adherence rate from this study was significantly higher than the adherence from metastatic settings. Adherence-enhancing interventions for capecitabine in XELOX treatment as adjuvant therapy comprised management of nausea\/vomiting and diarrhea.<\/jats:p>","DOI":"10.3727\/096504017x15012905098071","type":"journal-article","created":{"date-parts":[[2017,8,2]],"date-time":"2017-08-02T11:16:30Z","timestamp":1501672590000},"page":"1625-1631","source":"Crossref","is-referenced-by-count":20,"title":["Self-Reported Adherence to Capecitabine on XELOX Treatment as Adjuvant Therapy for Colorectal Cancer"],"prefix":"10.32604","volume":"25","author":[{"given":"Kazuyoshi","family":"Kawakami","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Yokokawa","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahito","family":"Sugisaki","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsukuni","family":"Suenaga","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Chemotherapy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensei","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Chemotherapy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayaka","family":"Inoue","sequence":"additional","affiliation":[{"name":"Section for Practical Education, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Machida","sequence":"additional","affiliation":[{"name":"Section for Practical Education, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiharu","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Chemotherapy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Hama","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"17807","reference":[{"key":"b1","first-page":"1122","article-title":"Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU\/LV in Dukes\u2019 C colon cancer: The X-ACT trial","volume":"9","year":"2006","journal-title":"Br J Cancer"},{"key":"b2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/annonc\/mdj044","article-title":"Patients\u2019 preference for administration of endocrine treatments by injection or tablets: Results from a study of women with breast cancer","volume":"17","year":"2006","journal-title":"Ann Oncol."},{"key":"b3","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3322\/caac.20004","article-title":"Patient adherence and persistence with oral anticancer treatment","volume":"59","year":"2009","journal-title":"CA Cancer J Clin."},{"key":"b4","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1186\/s13104-015-1231-8","article-title":"Adherence to oral anticancer chemotherapy: What influences patients\u2019 over or non-adherence? Analysis of the OCTO study through quantitative\u2013qualitative methods","volume":"8","year":"2015","journal-title":"BMC Res Notes"},{"key":"b5","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1200\/JCO.2006.08.1075","article-title":"Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: A planned safety analysis in 1,864 patients","volume":"25","year":"2007","journal-title":"J Clin Oncol."},{"key":"b6","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3109\/0284186X.2013.844353","article-title":"Adherence and patients\u2019 experiences with the use of oral anticancer agents","volume":"53","year":"2014","journal-title":"Acta Oncol."},{"key":"b7","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.ctrv.2012.12.014","article-title":"Determinants and associated factors influencing medication adherence and persistence to oral anticancer drugs: A systematic review","volume":"39","year":"2013","journal-title":"Cancer Treat Rev."},{"key":"b8","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.1990.8.12.1935","article-title":"The calculation of received dose intensity","volume":"8","year":"1990","journal-title":"J Clin Oncol."},{"key":"b9","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1200\/JCO.2015.60.9107","article-title":"Capecitabine plus oxaliplatin compared with fluorouracil\/folinic acid as adjuvant therapy for stage III colon cancer: Final results of the NO16968 randomized controlled phase III trial","volume":"33","year":"2015","journal-title":"J Clin Oncol."},{"key":"b10","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1159\/000448717","article-title":"Self-reported adherence to trifluridine and tipiracil hydrochloride for metastatic colorectal cancer: A retrospective cohort study","volume":"91","year":"2016","journal-title":"Oncology"},{"key":"b11","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1200\/JCO.2010.33.6297","article-title":"Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer","volume":"29","year":"2011","journal-title":"J Clin Oncol."},{"key":"b12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000328317","article-title":"Self-reported compliance with capecitabine: Findings from a prospective cohort analysis","volume":"80","year":"2011","journal-title":"Oncology"},{"key":"b13","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s00520-010-0927-5","article-title":"Enhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical care","volume":"19","year":"2011","journal-title":"Support Care Cancer"},{"key":"b14","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1056\/NEJMoa0810266","article-title":"Adjuvant chemotherapy in older women with early-stage breast cancer","volume":"360","year":"2009","journal-title":"N Engl J Med."},{"key":"b15","first-page":"561","article-title":"Patients\u2019 self-reported adherence to capecitabine on XELOX treatment in metastatic colorectal cancer: Findings from a retrospective cohort analysis","volume":"9","year":"2015","journal-title":"Patient Prefer Adherence"},{"key":"b16","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s10549-010-1132-4","article-title":"Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer","volume":"126","year":"2011","journal-title":"Breast Cancer Res Treat."},{"key":"b17","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1038\/bjc.2012.389","article-title":"Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: A retrospective cohort study in Catalonia, Spain","volume":"107","year":"2012","journal-title":"Br J Cancer"},{"key":"b18","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication","volume":"353","year":"2005","journal-title":"N Engl J Med."},{"key":"b19","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/j.1365-2354.2010.01212.x","article-title":"Adherence with oral chemotherapy: Results from a qualitative study of the behaviour and representations of patients and oncologists","volume":"20","year":"2011","journal-title":"Eur J Cancer Care"},{"key":"b20","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/cas.12146","article-title":"Risk factors of chemotherapy-induced nausea and vomiting: Index for personalized antiemetic prophylaxis","volume":"104","year":"2013","journal-title":"Cancer Sci."},{"key":"b21","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.canep.2014.03.012","article-title":"Adherence influencing factors in patients taking oral anticancer agents: A systematic review","volume":"38","year":"2014","journal-title":"Cancer Epidemiol."},{"key":"b22","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10549-010-0952-6","article-title":"Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer","volume":"125","year":"2011","journal-title":"Breast Cancer Res Treat."},{"key":"b23","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1016\/j.ejca.2006.03.004","article-title":"Intentional and non-intentional non-adherence to medication amongst breast cancer patients","volume":"42","year":"2006","journal-title":"Eur J Cancer"},{"key":"b24","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","article-title":"Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: The ADAGIO study","volume":"113","year":"2009","journal-title":"Blood"},{"key":"b25","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2165\/00019053-200725060-00004","article-title":"Treatment interruptions and non-adherence with imatinib and associated healthcare costs: A retrospective analysis among managed care patients with chronic myelogenous leukemia","volume":"25","year":"2007","journal-title":"Pharmacoeconomics"},{"key":"b26","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jnci.2012.10.003","article-title":"Clinico-pathological features of breast carcinoma in elderly Egyptian patients: A comparison with the non-elderly using population-based data","volume":"25","year":"2013","journal-title":"J Egypt Natl Cancer Inst."},{"key":"b27","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/bjc.2012.348","article-title":"Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: An observational patient-centered outcome study","volume":"107","year":"2012","journal-title":"Br J Cancer"},{"key":"b28","volume-title":"Adherence to long-term therapies: Evidence for action","year":"2003"},{"key":"b29","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/phar.1399","article-title":"Improving adherence to oral cancer therapy in clinical practice","volume":"34","year":"2014","journal-title":"Pharmacotherapy"},{"key":"b30","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.thromres.2015.07.007","article-title":"Self-reported adherence to anticoagulation and its determinants using the Morisky Medication Adherence Scale","volume":"136","year":"2015","journal-title":"Thromb Res."},{"key":"b31","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/bjd.13377","article-title":"Poor adherence to oral and topical medication in 3069 dermatological patients as assessed by the Morisky Medication Adherence Scale-8","volume":"172","year":"2015","journal-title":"Br J Dermatol."},{"key":"b32","article-title":"Patient-reported adherence to adjuvant aromatase inhibitor therapy using the Morisky Medication Adherence Scale: An evaluation of predictors","year":"2016","journal-title":"Am J Clin Oncol."},{"key":"b33","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1016\/j.ejca.2015.06.113","article-title":"Association between self-report adherence measures and oestrogen suppression among breast cancer survivors on aromatase inhibitors","volume":"51","year":"2015","journal-title":"Eur J Cancer"}],"container-title":["Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.techscience.com\/uploads\/attached\/file\/20240530\/20240530181533_47834.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T21:35:45Z","timestamp":1733520945000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.techscience.com\/or\/v25n9\/56947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,2]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,11,2]]}},"alternative-id":["0965-0407(20171102)25:9L.1625;1-"],"URL":"https:\/\/doi.org\/10.3727\/096504017x15012905098071","relation":{},"ISSN":["0965-0407"],"issn-type":[{"value":"0965-0407","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11,2]]}}}